Labcorp Holdings Inc. has announced the nationwide availability of the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first blood-based in-vitro diagnostic test cleared by the U.S. Food and Drug Administration (FDA) to aid in diagnosing Alzheimer's disease. Developed by Fujirebio Diagnostics, Inc., the test offers early detection of amyloid plaques associated with Alzheimer's in adults aged 50 and older who show signs of cognitive decline. This FDA clearance marks a significant advancement in accessible and less invasive diagnostic options, as the test requires only a simple blood draw. The test is available at Labcorp's over 2,200 Patient Service Centers nationwide.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.